Advertisement

Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review

      Abstract

      Purpose

      Levothyroxine (LT4) is a drug with a narrow therapeutic index, applied in small amounts (micrograms), which makes interactions in the absorption phase clinically significant. The main aim of this article was to review and present the latest information on factors that affect the gastrointestinal absorption of this drug.

      Methods

      Relevant data were collected by using the MEDLINE, PubMed, EMBASE, Web of Science, Science Direct, and Scopus databases with the key words levothyroxine and absorption. Searches were not limited to specific publication types, study designs, dates, or languages. The reports were highly variable in the amount of information provided regarding study design and methods. Because of the heterogeneity of studies, no statistical analysis was performed.

      Findings

      Many gastrointestinal disorders, such as celiac disease, atrophic gastritis, lactose intolerance, and Helicobacter pylori infection, may impede the absorption of levothyroxine. During treatment of these disorders, it is necessary to monitor serum thyroid-stimulating hormone and free T4 values to reduce the risk of developing iatrogenic hyperthyroidism. Soybeans and coffee have the greatest impact on the reduction of absorption, whereas vitamin C has the ability to increase it. Conversely, the effect of dietary fiber on the absorption of LT4 is not yet fully understood; further research is needed on this topic. A decrease in the absorption of LT4 is established and clinically significant when administered concomitantly with cholestyramine, colesevelam, lanthanum, calcium carbonate, calcium citrate, calcium acetate, iron sulfate, ciprofloxacin, aluminum hydroxide, sevelamer, or proton pump inhibitors. This effect should be taken into consideration when prescribing these drugs concomitantly with LT4. The effects of Giardia lamblia infection and the influence of orlistat, polystyrene sulfonate, raloxifene, and simethicone on absorption of LT4 have been poorly documented. For bariatric surgery, sucralfate and H2-antagonist interactions are not well founded or contradictory evidence is available regarding their existence; additional research should be conducted.

      Implications

      The majority of the interactions are clinically significant. They are based on the LT4 adsorption on interfering substances in the digestive tract, as well as a consequently reduced amount of the drug available for absorption. These interactions can be avoided by separating the administration of LT4 and the interfering substance.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jonklaas J.
        • Bianco A.C.
        • Bauer A.J.
        • et al.
        Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement.
        Thyroid. 2014; 24: 1670-1751
        • Jonklaas J.
        Update on the treatment of hypothyroidism.
        Curr Opin Oncol. 2016; 28: 18-25
        • Liwanpo L.
        • Hershman J.M.
        Conditions and drugs interfering with thyroxine absorption.
        Best Pract Res Clin Endocrinol Metab. 2009; 23: 781-792
        • Ward L.S.
        The difficult patient: Drug interaction and the influence of concomitant diseases on the treatment of hypothyroidism.
        Arq Brasil Endocrinol Metab. 2010; 54: 435-442
        • Benvenga S.
        When thyroid hormone replacement is ineffective?.
        Curr Opin Endocrinol Diabetes Obes. 2013; 20: 467-477
        • Hays M.T.
        • Nielsen K.R.
        Human thyroxine absorption: age effects and methodological analyses.
        Thyroid. 1994; 4: 55-64
        • Benvenga S.
        • Bartolone L.
        • Squadrito S.
        • et al.
        Delayed intestinal absorption of levothyroxine.
        Thyroid. 1995; 5: 249-253
      1. El-Kattan A, Varma M. (2012) Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability. In J. Paxton (Ed.) Topics on Drug Metabolism. InTech, 10.5772/31087. http://www.intechopen.com/books/topics-on-drug-metabolism/oral-absorption-intestinal-metabolism-and-human-oral-bioavailability

        • Ilertz A.
        Food effects on drug absorption and dosage form performance.
        in: Dressman J.B. Reppas C. Oral drug absorption prediction and assessment. Second Edition. Informa Healthcare USA, Inc, New York2010
        • Lilja J.J.
        • Laitinen K.
        • Neuvonen P.J.
        Effects of grapefruit juice on the absorption of levothyroxine.
        Br J Clin Pharmacol. 2005; 60: 337-341
        • Bailey D.G.
        Fruit juice inhibition of uptake transport: a new type of food-drug interaction.
        Br J Clin Pharmacol. 2010; 70: 645-655
      2. Food and Drug Administration (2016) Medication Error Reports. http://www.fda.gov/Drugs/DrugSafety/MedicationErrors/ucm080629.htm. Accessed October 24, 2016.

        • Virili C.
        • Trimboli P.
        • Romanelli F.
        • Centanni M.
        Liquid and softgel levothyroxine use in clinical practice: state of the art.
        Endocrine. 2016; 54: 3-14
        • Brancato D.
        • Scorsone A.
        • Saura G.
        • et al.
        Comparison of TSH levels with liquid formulation versus tablet formulations of levothyroxine in the treatment of adult hypothyroidism.
        Endocr Pract. 2014; 20: 657-662
        • Peroni E.
        • Vigone M.C.
        • Mora S.
        • et al.
        Congenital hypothyroidism treatment in infants: a comparative study between liquid and tablet formulations of levothyroxine.
        Horm Res Paediatr. 2014; 81: 50-54
        • Vita R.
        • Saraceno G.
        • Trimarchi F.
        • Benvenga S.
        A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.
        Endocrine. 2013; 43: 154-160
        • Pirola I.
        • Formenti A.M.
        • Gandossi E.
        • et al.
        Oral liquid L-thyroxine (L-T4) may be better absorbed compared to L-T4 tablets following bariatric surgery.
        Obes Surg. 2013; 23: 1493-1496
        • Seng Yue C.
        • Benvenga S.
        • Scarsi C.
        • et al.
        When bioequivalence in healthy volunteers may not translate to bioequivalence in patients: differential effects of increased gastric pH on the pharmacokinetics of levothyroxine capsules and tablets.
        J Pharm Sci. 2015; 18: 844-855
        • Vita R.
        • Fallahi P.
        • Antonelli A.
        • Benvenga S.
        The administration of L-thyroxine as soft gel capsule or liquid solution.
        Expert Opin Drug Deliv. 2014; 11: 1103-1111
        • Vita R.
        • Benvenga S.
        Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule.
        Endocr Pract. 2014; 20: e38-e41
        • Santaguida M.G.
        • Virili C.
        • Del Duca S.C.
        • et al.
        Thyroxine softgel capsule in patients with gastric-related T4 malabsorption.
        Endocrine. 2015; 49: 51-57
        • Vita R.
        • Saraceno G.
        • Trimarchi F.
        • Benvenga S.
        Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors.
        J Clin Endocrinol Metab. 2014; 99: 4481-4486
        • Bolk N.
        • Visser T.J.
        • Nijman J.
        • et al.
        Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial.
        Arch Intern Med. 2010; 170: 1996-2003
        • Rajput R.
        • Chatterjee S.
        • Rajput M.
        Can levothyroxine be taken as evening dose? Comparative evaluation of morning versus evening dose of levothyroxine in treatment of hypothyroidism.
        J Thyroid Res. 2011; 2011: 505239
        • Bach-Huynh T.G.
        • Nayak B.
        • Loh J.
        • Soldin S.
        • et al.
        Timing of levothyroxine administration affects serum thyrotropin concentration.
        J Clin Endocrinol Metab. 2009; 94: 3905-3912
        • Perez C.L.
        • Araki F.S.
        • Graf H.
        • de Carvalho G.A.
        Serum thyrotropin levels following levothyroxine administration at breakfast.
        Thyroid. 2013; 23: 779-784
        • Elliott D.P.
        Effect of levothyroxine administration time on serum TSH in elderly patients.
        Ann Pharmacother. 2001; 35: 529-532
        • Centanni M.
        • Gargano L.
        • Canettieri G.
        • et al.
        Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis.
        N Engl J Med. 2006; 354: 1787-1795
        • Hadithi M.
        • de Boer H.
        • Meijer J.W.
        • et al.
        Coeliac disease in Dutch patients with Hashimoto׳s thyroiditis and vice versa.
        World J Gastroenterol. 2007; 21: 1715-1722
        • Ch׳ng C.L.
        • Jones M.K.
        • Kingham J.G.
        Celiac disease and autoimmune thyroid disease.
        Clin Med Res. 2007; 5: 184-192
        • Betterle C.
        • Dal Pra C.
        • Mantero F.
        • Zanchetta R.
        Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction.
        Endocr Rev. 2002; 23: 327-364
        • Silva C.M.
        • Souza M.V.
        Autoimmune hypothyroidism nonresponsive to high doses of levothyroxine and severe hypocalcemia.
        Arq Bras Endocrinol Metabol. 2005; 49: 599-603
        • Virili C.
        • Bassotti G.
        • Santaguida M.G.
        • et al.
        Atypical celiac disease as cause of increased need for thyroxine: a systematic study.
        J Clin Endocrinol Metab. 2012; 97: E419-E422
        • Collins D.
        • Wilcox R.
        • Nathan M.
        • Zubarik R.
        Celiac disease and hypothyroidism.
        Am J Med. 2012; 125: 278-282
        • Mearin M.L.
        • Ivarsson A.
        • Dickey W.
        Coeliac disease: is it time for mass screening?.
        Best Pract Res Clin Gastroenterol. 2005; 19: 441-452
        • McDermott J.H.
        • Coss A.
        • Walsh C.H.
        Celiac disease presenting as resistant hypothyroidism.
        Thyroid. 2005; 15: 386-388
        • d׳Estève-Bonetti L.
        • Bennet A.P.
        • Malet D.
        • et al.
        Gluten-induced enteropathy (coeliac disease) revealed by resistance to treatment with levothyroxine and alfacalcidol in a sixty-eight-year-old patient: a case report.
        Thyroid. 2002; 12: 633-636
        • Caputo M.
        • Brizzolara R.
        • Schiavo M.
        • et al.
        Occurrence of overt celiac disease in the elderly following total thyroidectomy.
        J Endocrinol Invest. 2006; 29: 831-833
        • Muñoz-Torres M.
        • Varsavsky M.
        • Alonso G.
        Lactose intolerance revealed by severe resistance to treatment with levothyroxine.
        Thyroid. 2006; 16: 1171-1173
        • Montalto M.
        • Gallo A.
        • Santoro L.
        • et al.
        Low-dose lactose in drugs neither increases breath hydrogen excretion nor causes gastrointestinal symptoms.
        Aliment Pharmacol Ther. 2008; 28: 1003-1012
        • Asik M.
        • Gunes F.
        • Binnetoglu E.
        • et al.
        Decrease in TSH levels after lactose restriction in Hashimoto׳s thyroiditis patients with lactose intolerance.
        Endocrine. 2014; 46: 279-284
        • Cellini M.
        • Santaguida M.G.
        • Gatto I.
        • et al.
        Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine.
        J Clin Endocrinol Metab. 2014; 99: E1454-E1458
        • Lahner E.
        • Virili C.
        • Santaguida M.G.
        • et al.
        Helicobacter pylori infection and drugs malabsorption.
        World J Gastroenterol. 2014; 20: 10331-10337
        • Dietrich J.W.
        • Gieselbrecht K.
        • Holl R.W.
        • Boehm B.O.
        Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy.
        Horm Metab Res. 2006; 38: 57-59
        • Bugdaci M.S.
        • Zuhur S.S.
        • Sokmen M.
        • et al.
        The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine.
        Helicobacter. 2011; 16: 124-130
        • Seppel T.
        • Rose F.
        • Schlaghecke R.
        Chronic intestinal giardiasis with isolated levothyroxine malabsorption as reason for severe hypothyroidism—implications for localization of thyroid hormone absorption in the gut.
        Exp Clin Endocrinol Diabetes. 1996; 104: 180-182
        • de Figueiredo Radaeli R.
        • Diehl L.A.
        Increased levothyroxine requirement in a woman with previously well-controlled hypothyroidism and intestinal giardiasis.
        Arq Bras Endocrinol Metabol. 2011; 55: 81-84
        • Samuel I.
        • Mason E.E.
        • Renquist K.E.
        • et al.
        Bariatric surgery trends: an 18-year report from the International Bariatric Surgery Registry.
        Am J Surg. 2006; 192: 657-662
        • Padwal R.
        • Brocks D.
        • Sharma A.M.
        A systematic review of drug absorption following bariatric surgery and its theoretical implications.
        Obes Rev. 2010; 11: 41-50
        • Rubio I.G.
        • Galrão A.L.
        • Santo M.A.
        • et al.
        Levothyroxine absorption in morbidly obese patients before and after Roux-En-Y gastric bypass (RYGB) surgery.
        Obes Surg. 2012; 22: 253-258
        • Gkotsina M.
        • Michalaki M.
        • Mamali I.
        • et al.
        Improved levothyroxine pharmacokinetics after bariatric surgery.
        Thyroid. 2013; 23: 414-419
        • US Department of Health and Human Services, Food and Drug Administration, CDER
        Food-effect bioavailability and fed bioequivalence studies.
        Guidance for industry. U.S. DHHS, FDA, CDER, Rockville, MD2002: 1-9
      3. Agency for Medicinal Products and Medical Devices. (2015) Euthyrox 100 µg tablets http://www.halmed.hr/upl/lijekovi/SPC/UP-I-530-09-14-01-218.pdf. Accessed January 10, 2015.

        • Seechurn S.
        • Sharma S.
        • Oyibo S.
        Administration of levothyroxine 45–60 min before breakfast improves biochemical availability as evidenced by reduced thyrotropin levels.
        Open J Endocr Metab Dis. 2012; 2: 36-39
        • Dickerson R.N.
        • Maish G.O.
        • Minard G.
        • Brown R.O.
        Clinical relevancy of the levothyroxine-continuous enteral nutrition interaction.
        Nutr Clin Pract. 2010; 25: 646-652
        • Wenzel K.W.
        • Kirschsieper H.E.
        Aspects of the absorption of oral L-thyroxine in normal man.
        Metab Clin Exp. 1977; 26: 1-8
        • Liel Y.
        • Harman-Boehm I.
        • Shany S.
        Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients.
        J Clin Endocrinol Metab. 1996; 81: 857-859
        • Benvenga S.
        • Bartolone L.
        • Pappalardo M.A.
        • et al.
        Altered intestinal absorption of L-thyroxine caused by coffee.
        Thyroid. 2008; 18: 293-301
        • Chiu A.C.
        • Sherman S.I.
        Effects of pharmacological fiber supplements on levothyroxine absorption.
        Thyroid. 1998; 8: 667-671
        • Pinchera A.
        • MacGillivray M.H.
        • Crawford J.D.
        • et al.
        Thyroid refractoriness in an athyreotic cretin fed soybean formula.
        New Engl J Med. 1965; 273: 83-87
        • Fruzza A.G.
        • Demeterco-Berggren C.
        • Jones K.L.
        Unawareness of the effects of soy intake on the management of congenital hypothyroidism.
        Pediatrics. 2012; 130: e699-e702
        • Jabbar M.A.
        • Larrea J.
        • Shaw R.A.
        Abnormal thyroid function tests in infants with congenital hypothyroidism: the influence of soy-based formula.
        J Am Coll Nutr. 1997; 16: 280-282
        • Chorazy P.A.
        • Himelhoch S.
        • Hopwood N.J.
        • et al.
        Persistent hypothyroidism in an infant receiving a soy formula: case report and review of the literature.
        Pediatrics. 1995; 96: 148-150
        • Conrad S.C.
        • Chiu H.
        • Silverman B.L.
        Soy formula complicates management of congenital hypothyroidism.
        Arch Dis Child. 2004; 89: 37-40
        • Bell D.S.
        • Ovalle F.
        Use of soy protein supplement and resultant need for increased dose of levothyroxine.
        Endocr Pract. 2001; 7: 193-194
        • Antúnez P.B.
        • Licht S.D.
        Vitamin C improves the apparent absorption of levothyroxine in a subset of patients receiving this hormone for primary hypothyroidism.
        Rev Argent Endocrinol Metab. 2011; 48: 16-24
        • Jubiz W.
        • Ramirez M.
        Effect of vitamin C on the absorption of levothyroxine in patients with hypothyroidism and gastritis.
        J Clin Endocrinol Metab. 2014; 99: E1031-E1034
      4. Lexicomp® [database on the Internet] Hudson, OH, USA: Lexicomp, Inc; 2013. (2015). http://webstore.lexi.com/Information/Product-Information/Lexi-Drugs-and-Lexi-Interact-Details. Accessed February 12, 2015.

      5. MICROMEDEX® Gateway [database on the Internet] Greenwood Village, CO, USA: Thomson Reuters. (2013). http://www.thomsonhc.com/home. Accessed February 12, 2015.

        • Sperber A.D.
        • Liel Y.
        Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide.
        Arch Intern Med. 1992; 152: 183-184
        • Liel Y.
        • Sperber A.D.
        • Shany S.
        Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide.
        Am J Med. 1994; 97: 363-365
        • Mersebach H.
        • Rasmussen A.K.
        • Kirkegaard L.
        • Feldt-Rasmussen U.
        Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments.
        Pharmacol Toxicol. 1999; 84: 107-109
        • Zamfirescu I.
        • Carlson H.E.
        Absorption of levothyroxine when coadministered with various calcium formulations.
        Thyroid. 2011; 21: 483-486
        • Singh N.
        • Weisler S.L.
        • Hershman J.M.
        The acute effect of calcium carbonate on the intestinal absorption of levothyroxine.
        Thyroid. 2001; 11: 967-971
        • Singh N.
        • Singh P.N.
        • Hershman J.M.
        Effect of calcium carbonate on the absorption of levothyroxine.
        JAMA. 2000; 283: 2822-2825
        • Schneyer C.R.
        Calcium carbonate and reduction of levothyroxine efficacy.
        JAMA. 1998; 279: 750
        • Mazokopakis E.E.
        • Giannakopoulos T.G.
        • Starakis I.K.
        Interaction between levothyroxine and calcium carbonate.
        Can Fam Physician. 2008; 54: 39
        • Butner L.E.
        • Fulco P.P.
        • Feldman G.
        Calcium carbonate-induced hypothyroidism.
        Ann Intern Med. 2000; 132: 595
        • Diskin C.J.
        • Stokes T.J.
        • Dansby L.M.
        • et al.
        Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement.
        Int Urol Nephrol. 2007; 39: 599-602
        • Campbell N.R.
        • Hasinoff B.B.
        • Stalts H.
        • et al.
        Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism.
        Ann Intern Med. 1992; 117: 1010-1013
        • Shakir K.M.
        • Chute J.P.
        • Aprill B.S.
        • Lazarus A.A.
        Ferrous sulfate-induced increase in requirement for thyroxine in a patient with primary hypothyroidism.
        South Med J. 1997; 90: 637-639
        • Schlienger J.L.
        Increased need for thyroxine induced by iron sulfate.
        Presse Med. 1994; 23: 492
        • Fiaux E.
        • Kadri K.
        • Levasseur C.
        • et al.
        Hypothyroidism as the result of drug interaction between ferrous sulfate and levothyroxine.
        Rev Med Interne. 2010; 31: e4-e5
        • Weitzman S.P.
        • Ginsburg K.C.
        • Carlson H.E.
        Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine.
        Thyroid. 2009; 19: 77-79
      6. Medicines and Healthcare Products Regulatory Agency (2015) SPC-DOC_PL 08081-0044.PDF. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1386830026231.pdf. Accessed January 28, 2015.

        • Madhava K.
        • Hartley A.
        Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine.
        Clin Oncol (R Coll Radiol). 2005; 17: 492
      7. Medicines and Healthcare Products Regulatory Agency (2015) SPC-DOC_PL 30306-0380.PDF. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1426827504895.pdf. Accessed January 28, 2015.

        • Mclean M.
        • Kirkwood I.
        • Epstein M.
        • et al.
        Cation-exchange resin and inhibition of intestinal absorption of thyroxine.
        Lancet. 1993; 341: 1286
        • Siraj E.S.
        • Gupta M.K.
        • Reddy S.S.
        Raloxifene causing malabsorption of levothyroxine.
        Arch Intern Med. 2003; 163: 1367-1370
        • Garwood C.L.
        • Van Schepen K.A.
        • Mcdonough R.P.
        • Sullivan A.L.
        Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene.
        Pharmacotherapy. 2006; 26: 881-885
        • Kaykhaei M.A.
        • Shams M.
        • Sadegholvad A.
        • et al.
        Low doses of cholestyramine in the treatment of hyperthyroidism.
        Endocrine. 2008; 34: 52-55
        • Hagag P.
        • Nissenbaum H.
        • Weiss M.
        Role of colestipol in the treatment of hyperthyroidism.
        J Endocrinol Invest. 1998; 21: 725-731
        • Brown K.S.
        • Armstrong I.C.
        • Wang A.
        • et al.
        Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen, estradiol, norethindrone, levothyroxine, and glyburide.
        J Clin Pharmacol. 2010; 50: 554-565
        • Northcutt R.C.
        • Stiel J.N.
        • Hollifield J.W.
        • Stant E.G.
        The influence of cholestyramine on thyroxine absorption.
        JAMA. 1969; 208: 1857-1861
        • Harmon S.M.
        • Seifert C.F.
        Levothyroxine-cholestyramine interaction reemphasized.
        Ann Intern Med. 1991; 115: 658-659
        • Rosenberg R.
        Malabsorption of thyroid hormone with cholestyramine administration.
        Conn Med. 1994; 58: 109
        • Shakir K.M.
        • Michaels R.D.
        • Hays J.H.
        • Potter B.B.
        The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism.
        Ann Intern Med. 1993; 118: 112-113
        • de Luis D.A.
        • Dueñas A.
        • Martin J.
        • et al.
        Light symptoms following a high-dose intentional L-thyroxine ingestion treated with cholestyramine.
        Horm Res. 2002; 57: 61
        • Arnadottir M.
        • Johannesson A.J.
        Phosphate binders and timing of levothyroxine administration.
        Nephrol Dial Transplant. 2008; 23: 420
        • John-Kalarickal J.
        • Pearlman G.
        • Carlson H.E.
        New medications which decrease levothyroxine absorption.
        Thyroid. 2007; 17: 763-765
        • Balapatabendi M.
        • Harris D.
        • Shenoy S.D.
        Drug interaction of levothyroxine with infant colic drops.
        Arch Dis Child. 2011; 96: 888-889
        • Goldberg A.S.
        • Tirona R.G.
        • Asher L.J.
        • et al.
        Ciprofloxacin and rifampin have opposite effects on levothyroxine absorption.
        Thyroid. 2013; 23: 1374-1378
        • Cooper J.G.
        • Harboe K.
        • Frost S.K.
        • Skadberg Ø.
        Ciprofloxacin interacts with thyroid replacement therapy.
        BMJ. 2005; 330: 1002
        • Nolan S.R.
        • Self T.H.
        • Norwood J.M.
        Interaction between rifampin and levothyroxine.
        South Med J. 1999; 92: 529-531
        • Takasu N.
        • Kinjou Y.
        • Kouki T.
        • et al.
        Rifampin-induced hypothyroidism.
        J Endocrinol Invest. 2006; 29: 645-649
        • Havrankova J.
        • Lahaie R.
        Levothyroxine binding by sucralfate.
        Ann Intern Med. 1992; 117: 445-446
        • Sherman S.I.
        • Tielens E.T.
        • Ladenson P.W.
        Sucralfate causes malabsorption of L-thyroxine.
        Am J Med. 1994; 96: 531-535
        • Khan F.
        • Jeanniton E.
        • Renedo M.
        Does sucralfate impede levothyroxine therapy.
        Ann Intern Med. 1993; 118: 317
        • Campbell J.A.
        • Schmidt B.A.
        • Bantle J.P.
        Sucralfate and the absorption of L-thyroxine.
        Ann Intern Med. 1994; 121: 152
        • Jonderko G.
        • Jonderko K.
        • Marcisz C.
        • Kotulska A.
        Effect of cimetidine and ranitidine on absorption of [125I] levothyroxine administered orally.
        Zhongguo Yao Li Xue Bao. 1992; 13: 391-394
        • Ananthakrishnan S.
        • Braverman L.E.
        • Levin R.M.
        • et al.
        The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption.
        Thyroid. 2008; 18: 493-498
        • Irving S.A.
        • Vadiveloo T.
        • Leese G.P.
        Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS).
        Clin Endocrinol (Oxf). 2015; 82: 136-141
        • Sachmechi I.
        • Reich D.M.
        • Aninyei M.
        • et al.
        Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism.
        Endocr Pract. 2007; 13: 345-349
        • Trifirò G.
        • Parrino F.
        • Sultana J.
        • et al.
        Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice.
        Clin Drug Invest. 2015; 35: 187-195
        • Pabla D.
        • Akhlaghi F.
        • Zia H.
        A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry.
        Eur J Pharm Biopharm. 2009; 72: 105-110
        • Colucci P.
        • Seng Yue C.
        • Ducharme M.
        • Benvenga S.
        A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism.
        Eur Endocrinol. 2013; 9: 40-47